NuCana Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de NuCana de 41.4% y 71.5% respectivamente, mientras que el BPA crecerá en un 39.1% al año.

Información clave

41.4%

Tasa de crecimiento de los beneficios

39.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	23.7%
Tasa de crecimiento de los ingresos	71.5%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	01 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:NCNA - Estimaciones futuras de los analistas y datos financieros pasados (GBP Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	2	-29	N/A	N/A	4
12/31/2025	1	-26	N/A	N/A	4
12/31/2024	N/A	-24	N/A	N/A	4
12/31/2023	N/A	-28	-27	-26	N/A
9/30/2023	N/A	-35	-34	-33	N/A
6/30/2023	N/A	-33	-22	-22	N/A
3/31/2023	N/A	-31	-25	-25	N/A
12/31/2022	N/A	-32	-24	-23	N/A
9/30/2022	N/A	-30	-27	-26	N/A
6/30/2022	N/A	-34	-30	-29	N/A
3/31/2022	N/A	-39	-25	-24	N/A
12/31/2021	N/A	-41	-25	-24	N/A
9/30/2021	N/A	-39	-23	-23	N/A
6/30/2021	N/A	-40	-28	-27	N/A
3/31/2021	N/A	-36	-25	-23	N/A
12/31/2020	N/A	-31	-23	-22	N/A
9/30/2020	N/A	-26	-18	-17	N/A
6/30/2020	N/A	-22	-21	-20	N/A
3/31/2020	N/A	-20	-25	-24	N/A
12/31/2019	N/A	-21	-25	-24	N/A
9/30/2019	N/A	-17	-24	-22	N/A
6/30/2019	N/A	-16	-19	-18	N/A
3/31/2019	N/A	-13	-17	-16	N/A
12/31/2018	N/A	-14	-14	-12	N/A
9/30/2018	N/A	-15	-14	-13	N/A
6/30/2018	N/A	-26	-12	-11	N/A
3/31/2018	N/A	-28	-11	-10	N/A
12/31/2017	N/A	-23	-10	-9	N/A
9/30/2017	N/A	-20	N/A	-8	N/A
6/30/2017	N/A	-7	N/A	-8	N/A
3/31/2017	N/A	-6	N/A	-9	N/A
12/31/2016	N/A	-6	N/A	-9	N/A
12/31/2015	N/A	-5	N/A	-4	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que NCNA siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que NCNA siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que NCNA siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que NCNA no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que NCNA no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de NCNA se prevé que sea elevada dentro de 3 años.

NuCana Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 9.5% to US$4.79

Price target increased by 10% to US$4.38

Price target decreased to US$3.42

Price target decreased to US$4.26

Price target decreased to US$4.26

Price target decreased to US$4.69

Recent updates

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

Price target increased by 9.5% to US$4.79

Here's Why NuCana (NASDAQ:NCNA) Must Use Its Cash Wisely

Insufficient new directors

New major risk - Financial position

New major risk - Revenue and earnings growth

New major risk - Share price stability

Nucana plc Announces Presentation on Ongoing Nutide:701 Study of Nuc-7738 At the Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics 2023

We're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn Rate

NuCana plc Presents Encouraging Data on NUC-3373 in Colorectal Cancer At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Here's Why We're A Bit Worried About NuCana's (NASDAQ:NCNA) Cash Burn Situation

NuCana plc, Annual General Meeting, Jun 15, 2023

NuCana Announces Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Price target increased by 10% to US$4.38

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

Price target decreased to US$3.42

Price target decreased to US$4.26

NuCana plc Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

Price target decreased to US$4.26

NuCana: An Intriguing 'Sum Of The Parts' Story

Nucana Presents Promising Data on NUC-7738 At the European Society of Medical Oncology (Esmo) Annual Meeting 2022

NuCana GAAP EPS of -£0.07

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

NuCana regains Nasdaq compliance

NuCana: Improving Chemotherapy And A Major Patent Litigation Win Against Gilead

Price target decreased to US$4.69

NuCana Announces Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Less than half of directors are independent

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

Price target decreased to US$9.00

Price target decreased to US$11.67

NuCana Announces Update for Phase 3 Biliary Tract Cancer Study

NuCana plc Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study

We Think NuCana (NASDAQ:NCNA) Can Easily Afford To Drive Business Growth

NuCana: Preparing For A Critical 2022

Price target increased to US$17.25

We're Interested To See How NuCana (NASDAQ:NCNA) Uses Its Cash Hoard To Grow

NuCana: The Market Continues To Overlook Its ProTide Platform Technology

We Think NuCana (NASDAQ:NCNA) Can Afford To Drive Business Growth

Forecast to breakeven in 2025

New 90-day low: US$4.38

Companies Like NuCana (NASDAQ:NCNA) Are In A Position To Invest In Growth

NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer

New 90-day high: US$6.40

New 90-day low: US$4.40

NuCana plc Appoints Andrew Kay as Chairman of its Board of Directors

How Many NuCana plc (NASDAQ:NCNA) Shares Do Institutions Own?

Price target lowered to US$17.29

NuCana (NCNA) Investor Presentation - Slideshow

Nucana plc Announces Final Data from the Phase Ib Study of Acelarin Plus Cisplatin in Patients with Advanced Biliary Tract Cancer Published Online Ahead of Print in the Oncologist

Price target raised to US$19.00

NuCana reports Q3 results

New 90-day low: US$4.45

NuCana plc Announces the Appointment of Bali Muralidhar, M.D., Ph.D. to Its Board of Directors

NuCana plc Announces Data from Ongoing NUC-3373, NUC-7738 and Acelarin Phase III Study

New 90-day low: US$4.58

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento